Symbols

IPHA

Innate Pharma·NASDAQ

--(--)

IPHA fundamentals

IPHA Q4 2025 Earnings

Innate Pharma (IPHA) released its earnings on Mar 26, 2026: revenue was 5.70M (YoY --), met estimates; EPS was -0.3492 (YoY --), met estimates.

Revenue / YoY

5.70M

EPS / YoY

-0.3492

Report date

Mar 26, 2026

IPHA Earnings Call Summary for Q4,2025

Strategic Focus: Three assets (IPH4502, lacutamab, monalizumab) drive growth, with phase III trials for lacutamab (H2 2026) and monalizumab (data H2 2026).
Financial Strength: EUR 44.8M cash, funding until Q3 2026; AstraZeneca partnerships worth up to $2.16B in milestones.
Clinical Progress: IPH4502 shows activity in post-PADCEV bladder cancer; lacutamab trial design finalized for CTCL.
Partnership Updates: MATISSE trial interim data at AACR; lacutamab financing discussions prioritize shareholder value.

Earnings

EPS

Revenue

Revenue & Expenses

Key Indicators

Innate Pharma (IPHA) key financial stats and ratios, covering profitability, financial health, and leverage.

Income Statement

Innate Pharma (IPHA)'s revenue and profit trends over recent years, visualized with a waterfall chart to showcase the revenue-to-profit funnel.

Trend

Breakdown

Balance Sheet

Innate Pharma (IPHA)'s asset and liability trends over recent years, visualized with a waterfall chart to illustrate changes in its asset-liability structure.

Trend

Breakdown

Cash Flow

Innate Pharma (IPHA)'s cash flow trends over recent years, visualized with a waterfall chart to illustrate changes in its operating, investing, and financing cash flows.

Trend

Breakdown